Center for Global Infectious Disease Research

Neurologist Anthony Lang Presents Groundbreaking News on Parkinson's Disease at World Congress of Neurology 2023

Retrieved on: 
Tuesday, October 17, 2023

MONTREAL, Oct. 17, 2023 /PRNewswire/ -- During a plenary lecture at the 26th World Congress of Neurology , Dr. Anthony Lang, professor of neurology and Jack Clark Chair for Parkinson's Disease Research, University of Toronto, revealed a groundbreaking new model for identifying and studying Parkinson's disease.

Key Points: 
  • MONTREAL, Oct. 17, 2023 /PRNewswire/ -- During a plenary lecture at the 26th World Congress of Neurology , Dr. Anthony Lang, professor of neurology and Jack Clark Chair for Parkinson's Disease Research, University of Toronto, revealed a groundbreaking new model for identifying and studying Parkinson's disease.
  • "We believe this is a radically different way of looking at Parkinson's disease," said Lang.
  • Lang hopes this major step toward a biological model will drive research to investigate these biomarkers and give scientists a more complex understanding of the disease.
  • We need treatments that will slow the progression and change the natural course of these neurodegenerative diseases," said Lang.

Neurologist Anthony Lang Presents Groundbreaking News on Parkinson's Disease at World Congress of Neurology 2023

Retrieved on: 
Tuesday, October 17, 2023

MONTREAL, Oct. 17, 2023 /PRNewswire/ -- During a plenary lecture at the 26th World Congress of Neurology , Dr. Anthony Lang, professor of neurology and Jack Clark Chair for Parkinson's Disease Research, University of Toronto, revealed a groundbreaking new model for identifying and studying Parkinson's disease.

Key Points: 
  • MONTREAL, Oct. 17, 2023 /PRNewswire/ -- During a plenary lecture at the 26th World Congress of Neurology , Dr. Anthony Lang, professor of neurology and Jack Clark Chair for Parkinson's Disease Research, University of Toronto, revealed a groundbreaking new model for identifying and studying Parkinson's disease.
  • "We believe this is a radically different way of looking at Parkinson's disease," said Lang.
  • Lang hopes this major step toward a biological model will drive research to investigate these biomarkers and give scientists a more complex understanding of the disease.
  • We need treatments that will slow the progression and change the natural course of these neurodegenerative diseases," said Lang.

Rhode Island experts come together to discuss a new era of Alzheimer's disease treatment and research

Retrieved on: 
Wednesday, September 6, 2023

Maritza Ciliberto , member of the National Institutes of Health's National Advisory Council on Aging, AD care partner/research advocate and participant.

Key Points: 
  • Maritza Ciliberto , member of the National Institutes of Health's National Advisory Council on Aging, AD care partner/research advocate and participant.
  • Gregorio Valdez , Ph.D, GLF Translational Associate Professor of molecular biology, cell biology and biochemistry at Brown University.
  • In Rhode Island, some 24,000 people aged 65 and older are living with the disease, and 36,000 caregivers provide 51 million hours of unpaid care.
  • Organizations including Butler Hospital, the Rhode Island Department of Health and the Rhode Island Alzheimer's Association will be on-hand to share information, answer questions and connect attendees with relevant resources.

Lasher Family Gift Accelerates Innovative Infectious Disease Research and Education at Tampa General Hospital

Retrieved on: 
Wednesday, May 24, 2023

TAMPA, Fla., May 24, 2023 /PRNewswire/ -- Tampa General Hospital today announced a generous gift from the Lasher family of Tampa, Florida, to support the TGH Foundation and infectious disease research programs. This is a collaboration between Tampa General Hospital and the USF Health Morsani College of Medicine.

Key Points: 
  • TAMPA, Fla., May 24, 2023 /PRNewswire/ -- Tampa General Hospital today announced a generous gift from the Lasher family of Tampa, Florida, to support the TGH Foundation and infectious disease research programs.
  • Tampa General Hospital is committed to becoming a recognized global leader on the forefront of infectious disease clinical care, research, and education under the direction of Drs.
  • Kim is Tampa General director of Infectious Disease Research and director of the Division of Infectious Disease and International Medicine at the USF Health Morsani College of Medicine.
  • In addition to supporting current infectious disease research efforts, the Lasher family gift will accelerate Tampa General's research program, by attracting and recruiting the world's foremost infectious disease researchers who will bring their teams, intellectual property and grants to Tampa General.

Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.

Retrieved on: 
Thursday, February 2, 2023

CHATHAM, N.J., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has acquired all of the assets of Healion Bio, Inc. (Healion) including its entire portfolio of next-generation antiviral technology assets. Healion’s drug portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action. Host-directed antivirals modulate human cells and tissues and are different from direct-acting antivirals which inhibit virus proteins and processes. Tonix’s TNX-3900, formerly known as HB-121, are cathepsin protease inhibitors, some of which have strong activity in vitro against SARS-CoV-2.

Key Points: 
  • Healion’s drug portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action.
  • Host-directed antivirals modulate human cells and tissues and are different from direct-acting antivirals which inhibit virus proteins and processes.
  • Tonix’s TNX-3900, formerly known as HB-121, are cathepsin protease inhibitors, some of which have strong activity in vitro against SARS-CoV-2.
  • On behalf of the talented scientific team that I direct at our 48,000 square-foot cutting-edge infectious disease research facility in Frederick, Md., I am pleased to add this technology to the therapeutic development programs underway.”

Generate Biomedicines Grows Leadership Team with Head of Vaccines and Infectious Disease Research and Senior Vice President of Technical Operations

Retrieved on: 
Tuesday, November 22, 2022

Generate Biomedicines today announced that Daria Hazuda, Ph.D., has been named Head of Vaccines and Infectious Disease Research and Lisa Wyman has been named Senior Vice President of Technical Operations.

Key Points: 
  • Generate Biomedicines today announced that Daria Hazuda, Ph.D., has been named Head of Vaccines and Infectious Disease Research and Lisa Wyman has been named Senior Vice President of Technical Operations.
  • As the company advances into its next stage of growth, Dr. Hazuda is identifying and prioritizing the best applications of the Generate platform in vaccines and infectious disease research.
  • Prior to Ms. Wyman joining Generate, she served as the Senior Vice President of Technical Operations at Acceleron Pharma.
  • Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020.

Global Infectious Disease Diagnostics Market Forecast to 2028 - Players Include Danaher, Abbott, BD and Trinity Biotech - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 9, 2022

The "Global Infectious Disease Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Disease Indication, Technology, Testing Type, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Disease Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Disease Indication, Technology, Testing Type, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The report highlights trends prevailing in the market and factors driving the infectious disease diagnostics market growth.
  • However, the tedious and expensive process of infectious disease diagnostics development is restricting the infectious disease diagnostics market growth.
  • Based on disease indication, the global infectious disease diagnostics market , based on disease indication, is segmented into HIV, hepatitis, healthcare- associated infections (HAIs), human papillomavirus (HPV), tuberculosis (TB), influenza, and others disease indications.

International Forum On Non-alcoholic Liver Disease To Take Place In Santander By Researchers From The Valdecilla Research Institute (IDIVAL) and IS Global

Retrieved on: 
Friday, May 6, 2022

SANTANDER, Spain, May 6, 2022 /PRNewswire/ -- Since the forum is online, it intends to have a wider and more diverse audience both nationally and internationally.  Registration is completely free. This is the link to register:

Key Points: 
  • The International Precision Medicine Forum: Non-alcoholic fatty liver disease will be hosted by researchers from the Valdecilla Research Institute (IDIVAL), Paula Iruzubieta and Javier Crespo, and Jeff Lazarus, Head of Health Systems Research Group at IS Global of Barcelona (NAFLD).
  • Liver disease is one of the leading causes of lost years of working life in Europe, second only to ischemic heart disease.
  • And, without a doubt, non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in our environment.
  • This program offers a qualitative leap in the training of precision medicine and clinical research, thus offering advanced knowledge of the research process.

Biom Pharmaceuticals' Antiviral Compound Bi121 Shows Broad-spectrum Activity Against Three Variants of SARS-CoV-2

Retrieved on: 
Thursday, February 3, 2022

An antiviral formulation that has significant antiviral activity against current and future variants of SARS-CoV-2 is a global medical need.

Key Points: 
  • An antiviral formulation that has significant antiviral activity against current and future variants of SARS-CoV-2 is a global medical need.
  • After screening a prospective seventy-three herbal compounds from Biom Pharmaceutical's library, two preparations showed antiviral SARS-CoV-2 activity, of which Bi121 showed broad-spectrum activity.
  • Bi121 showed significant activity towards all three variants tested, in two different cell lines showing a broad-spectrum activity.
  • Biom Probiotics is marketing a dietary supplement that contains Bi121 together with Biom's gut microbiome diversifying prebiotics (Diversify), under the brand Biom D'Fend.

Global Infectious Diseases Partnering Analysis Report 2014-2021: Deal Trends, Players and Financials for Over 2,600 Deals - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 11, 2022

The "Global Infectious Diseases Partnering 2014-2021: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Diseases Partnering 2014-2021: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Infectious Diseases Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 2,600 infectious diseases deals.
  • The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
  • In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2014.